Premier Fund Managers Ltd Takes $693,000 Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Premier Fund Managers Ltd purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 6,458 shares of the medical equipment provider’s stock, valued at approximately $693,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Signaturefd LLC boosted its stake in shares of Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 92 shares in the last quarter. GAMMA Investing LLC boosted its position in Lantheus by 184.1% during the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 208 shares in the last quarter. UMB Bank n.a. boosted its position in Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after purchasing an additional 126 shares in the last quarter. Kathleen S. Wright Associates Inc. acquired a new stake in Lantheus in the third quarter valued at approximately $51,000. Finally, Nkcfo LLC purchased a new stake in shares of Lantheus in the second quarter valued at approximately $47,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on LNTH shares. JMP Securities dropped their price objective on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research note on Thursday, November 7th. StockNews.com upgraded Lantheus from a “hold” rating to a “buy” rating in a research report on Friday, November 8th. Truist Financial restated a “buy” rating and issued a $120.00 target price (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. B. Riley lifted their price target on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Finally, Redburn Atlantic began coverage on shares of Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective for the company. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $122.50.

Lantheus Stock Up 4.2 %

LNTH opened at $79.43 on Wednesday. The firm has a market cap of $5.52 billion, a P/E ratio of 13.22 and a beta of 0.51. The business has a fifty day simple moving average of $104.07 and a 200-day simple moving average of $96.66. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.